Hemant Phalak

Respect the hustle of Hemant Phalak-this dude’s the real deal in the startup world. So, he’s a YC S22 batch guy, which means he’s been through the grind and came out the other side crushing it. His background’s wild-started off at IIT Bombay, studying Material Sciences, which is kinda nerdy but also super technical. That technical depth? It’s what fuels his ability to build stuff that actually works.

Before jumping into the startup scene, Hemant was all about the hustle. He was at OYO, managing projects, helping them scale ops, and then he jumped into PwC India as a tech consultant. Dude’s been in the trenches, understanding how big companies tick and what it takes to make things run smoothly. Then he co-founded Zolve, a cross-border fintech, to make international banking easier. That’s where he learned the ropes of building expandable financial products and navigating regulatory stuff across countries-big brain moves.

But here’s where it gets crazy. Hemant’s now the Co-founder and Chief Product Officer at Entvin, a Y Combinator-backed startup that leverages AI to help pharma and life sciences companies cut through FDA red tape. Basically, they’re building AI agents to simplify compliance and speed up drug approvals. That’s some advanced shit. And they just raised $500K from YC in 2024-think about that, YC saw enough in this guy and his team to dump half a million bucks into their vision.

What does this say about Hemant? It’s simple-he’s driven by solving real problems, especially where tech and regulation collide. His process proves he’s not just in it for the money; he’s about pushing boundaries, making things faster, better, smarter. With a background in tech, finance, and now biotech, he’s got a serious hunger for tackling complex, high-impact problems. He’s the kind of founder who sees the chaos in regulation and thinks, “I can fix that,” then actually goes out and does it.

Bottom line? Hemant is one of those guys who’s been around the block, learned how to build shit that matters, and now he’s disrupting the pharma regulatory space with AI. He’s got the technical chops, the startup hustle, and the vision to change the game. No cap, he’s just getting started, and the future’s looking bright for him and Entvin.